Zinexts Life Science Corp.

Zinexts Life Science Corp. specializes in nucleic acid extraction kits for molecular diagnostics. These include automated and manual systems designed for extracting viral RNA, pathogen DNA, blood DNA, and DNA from formalin-fixed paraffin-embedded (FFPE) samples. Their products are tailored for high-throughput workflows, with variations supporting 48, 96, 192, or 960 samples, ensuring flexibility for different laboratory needs.

Zinexts Life Science Corp. is headquartered in Taiwan. While the company’s location determines its primary regulatory jurisdiction (e.g., adherence to Taiwan’s medical device regulations), its devices intended for use in the European Union are registered in the EUDAMED database. This registration reflects compliance with EU requirements for medical devices, ensuring traceability and transparency for authorized products within the EU market.

Zinexts Life Science Corp.’s devices are listed in the EUDAMED database, which is the official European Union registry for medical devices. This inclusion is required for devices marketed in the EU, as it provides transparency on manufacturers, authorized representatives, and device details. Since the company’s products fall under Class A classification in the EU—indicating low risk—registration ensures compliance with EU IVD (In Vitro Diagnostic) regulations while maintaining traceability for regulatory oversight.

Zinexts Life Science Corp.’s devices are classified as Class A under the EU’s medical device regulations. This classification applies to low-risk in vitro diagnostics, such as nucleic acid extraction kits, which pose minimal harm to patients or users. Class A devices undergo streamlined conformity assessment procedures, meaning they must meet essential requirements but typically require less rigorous pre-market evaluation than higher-risk devices. This classification reflects the company’s focus on foundational diagnostic tools used in molecular testing workflows.